Capecitabine-Induced Ileitis during Neoadjuvant Pelvic Radio-Chemotherapy for Locally Advanced Rectal Cancer: A Case Report with Literature Review.
capecitabine
concurrent radiochemotherapy
ileitis
radiation therapy
rectal cancer
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
10 10 2023
10 10 2023
Historique:
received:
25
09
2023
accepted:
07
10
2023
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
We report on a clinical case of capecitabine-induced acute ileitis in a patient treated with pre-operative concurrent chemoradiation with capecitabine for locally advanced rectal cancer and provide a comprehensive literature review. This a rare, but life-threatening, clinical situation, that clinicians should be aware of. Severe persistent diarrhea is the most frequent clinical feature and computed tomography is a valid tool for diagnosis. Conservative management includes capecitabine withdrawal, antidiarrheal therapy and endovenous hydration, together with dietary modifications and broad-spectrum antibiotics. Pelvic irradiation represents an adjunctive risk factor, which may increase the likelihood of occurrence of terminal ileitis. Early recognition and prompt intervention are crucial for successful clinical management.
Identifiants
pubmed: 37887555
pii: curroncol30100655
doi: 10.3390/curroncol30100655
pmc: PMC10605187
doi:
Substances chimiques
Capecitabine
6804DJ8Z9U
Types de publication
Review
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
9063-9077Références
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
World J Gastroenterol. 2013 Jan 14;19(2):185-98
pubmed: 23345941
Radiother Oncol. 1990 Aug;18(4):307-20
pubmed: 2244018
World J Surg Oncol. 2021 Nov 22;19(1):332
pubmed: 34809643
J Clin Oncol. 2009 Nov 1;27(31):5124-30
pubmed: 19770376
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
Clin Oncol (R Coll Radiol). 2010 Feb;22(1):70-83
pubmed: 19897345
Ned Tijdschr Geneeskd. 2011;155:A3064
pubmed: 21486509
Anticancer Drugs. 2008 Jun;19(5):447-64
pubmed: 18418212
J Gastrointest Cancer. 2018 Dec;49(4):538-542
pubmed: 28547118
Cancer Chemother Pharmacol. 1997;39(4):357-60
pubmed: 9025777
Case Rep Med. 2012;2012:154981
pubmed: 23251164
Pharmacogenomics. 2022 Dec;23(18):953-959
pubmed: 36382550
Case Rep Oncol. 2018 Oct 22;11(3):654-659
pubmed: 30483093
World J Gastrointest Endosc. 2019 May 16;11(5):383-388
pubmed: 31205599
Mol Clin Oncol. 2015 Nov;3(6):1398-1400
pubmed: 26807255
Cancer Res. 1993 Jul 1;53(13):3028-33
pubmed: 8391384
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2022 Sep 12;14(18):
pubmed: 36139585
Eur J Cancer. 2012 Aug;48(12):1781-90
pubmed: 22507892
Asia Pac J Clin Oncol. 2018 Jun;14(3):217-223
pubmed: 28856848
Curr Oncol. 2022 Sep 27;29(10):7021-7050
pubmed: 36290829
BMJ Case Rep. 2014 Apr 19;2014:
pubmed: 24748142
Ann Saudi Med. 2012 Nov-Dec;32(6):661-2
pubmed: 23396034
Clin Ther. 2005 Jan;27(1):23-44
pubmed: 15763604
J Clin Oncol. 2006 Oct 1;24(28):4620-5
pubmed: 17008704
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
Radiother Oncol. 2016 Aug;120(2):195-201
pubmed: 27528121
Acta Oncol. 1990;29(4):401-15
pubmed: 2202341
Cureus. 2021 Apr 21;13(4):e14621
pubmed: 34055501
Cancers (Basel). 2020 Nov 09;12(11):
pubmed: 33182445
Clin Transl Oncol. 2009 Aug;11(8):539-43
pubmed: 19661029